Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

p16-Positive oropharyngeal squamous cell carcinoma metastasis to the thyroid following complete chemoradiotherapy response: a case report and review of the literature.

Created on 30 Jul 2026

Authors

William H Cook, Anas A Linjawi, Veronika van Dijck

Published in

Journal of surgical case reports. Volume 2026. Issue 7. Pages rjag642. Epub Jul 29, 2026.

Abstract

Metastasis of oropharyngeal squamous cell carcinoma (OPSCC) to the thyroid gland is rare, and p16-positive cases form an even smaller subset. We present a case of p16-positive thyroid metastasis from OPSCC identified after complete treatment response. Nine months after completing chemoradiotherapy, the patient developed throat pain and hoarseness. Computed tomography demonstrated an enlarged heterogeneous right thyroid gland and fine needle aspiration confirmed p16-positive metastatic OPSCC in the absence of locoregional recurrence. The patient underwent extended total thyroidectomy and right selective neck dissection; formal pathology confirmed metastatic OPSCC with involved margins and 13/22 positive lymph nodes. To our knowledge, this is the first reported intrathyroidal metastasis from p16-positive OPSCC after complete treatment response and in the absence of local recurrence. Further cases are required to better understand the epidemiology, optimal management, and prognosis of this presentation.

PMID:
42529709
Bibliographic data and abstract were imported from PubMed on 30 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 10
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement